Charles Schwab Investment Management Inc. Increases Position in Edwards Lifesciences Corporation $EW

Charles Schwab Investment Management Inc. boosted its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 1.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,036,837 shares of the medical research company’s stock after purchasing an additional 75,194 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Edwards Lifesciences were worth $315,721,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $266,000. Avantax Advisory Services Inc. boosted its stake in Edwards Lifesciences by 10.7% during the 1st quarter. Avantax Advisory Services Inc. now owns 10,707 shares of the medical research company’s stock valued at $776,000 after acquiring an additional 1,032 shares during the last quarter. HB Wealth Management LLC grew its holdings in Edwards Lifesciences by 34.9% during the 1st quarter. HB Wealth Management LLC now owns 21,562 shares of the medical research company’s stock worth $1,563,000 after acquiring an additional 5,577 shares in the last quarter. LPL Financial LLC grew its holdings in Edwards Lifesciences by 23.9% during the 1st quarter. LPL Financial LLC now owns 324,351 shares of the medical research company’s stock worth $23,509,000 after acquiring an additional 62,671 shares in the last quarter. Finally, TCW Group Inc. increased its position in shares of Edwards Lifesciences by 20.0% in the 1st quarter. TCW Group Inc. now owns 27,440 shares of the medical research company’s stock worth $1,989,000 after purchasing an additional 4,575 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.5%

NYSE:EW opened at $84.70 on Tuesday. Edwards Lifesciences Corporation has a 12-month low of $65.94 and a 12-month high of $87.21. The firm has a market capitalization of $49.15 billion, a P/E ratio of 12.19, a P/E/G ratio of 3.97 and a beta of 1.03. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The business has a 50 day simple moving average of $78.97 and a 200 day simple moving average of $78.16.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period last year, the company earned $0.67 earnings per share. The firm’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on EW shares. The Goldman Sachs Group set a $104.00 price target on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 31st. Royal Bank Of Canada increased their target price on Edwards Lifesciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Piper Sandler reiterated an “overweight” rating and issued a $95.00 target price (up previously from $90.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $85.00 to $90.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Finally, Barclays restated an “overweight” rating and set a $99.00 price objective (up from $95.00) on shares of Edwards Lifesciences in a research note on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at $3,314,725.84. The trade was a 24.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.